These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 27469383)
21. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Yao X; Verkman AS Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662 [TBL] [Abstract][Full Text] [Related]
22. High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG. Miyazaki-Komine K; Takai Y; Huang P; Kusano-Arai O; Iwanari H; Misu T; Koda K; Mitomo K; Sakihama T; Toyama Y; Fujihara K; Hamakubo T; Yasui M; Abe Y Br J Pharmacol; 2016 Jan; 173(1):103-14. PubMed ID: 26398585 [TBL] [Abstract][Full Text] [Related]
24. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Kinoshita M; Nakatsuji Y; Kimura T; Moriya M; Takata K; Okuno T; Kumanogoh A; Kajiyama K; Yoshikawa H; Sakoda S Biochem Biophys Res Commun; 2009 Sep; 386(4):623-7. PubMed ID: 19545538 [TBL] [Abstract][Full Text] [Related]
25. NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases. Vaknin-Dembinsky A; Karussis D; Avichzer J; Abramsky O J Autoimmun; 2014 Nov; 54():93-9. PubMed ID: 25129503 [TBL] [Abstract][Full Text] [Related]
26. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Ahn SH; Kim SM; Sung JJ Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297 [TBL] [Abstract][Full Text] [Related]
28. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. Jacob A; McKeon A; Nakashima I; Sato DK; Elsone L; Fujihara K; de Seze J J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):922-30. PubMed ID: 23142960 [TBL] [Abstract][Full Text] [Related]
29. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. Kira J J Neurol Sci; 2011 Dec; 311(1-2):69-77. PubMed ID: 21962794 [TBL] [Abstract][Full Text] [Related]
30. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Jarius S; Paul F; Franciotta D; Waters P; Zipp F; Hohlfeld R; Vincent A; Wildemann B Nat Clin Pract Neurol; 2008 Apr; 4(4):202-14. PubMed ID: 18334978 [TBL] [Abstract][Full Text] [Related]
32. Experimental models of neuromyelitis optica. Bradl M; Lassmann H Brain Pathol; 2014 Jan; 24(1):74-82. PubMed ID: 24345221 [TBL] [Abstract][Full Text] [Related]
40. Screening, Synthesis, and In Vitro Evaluation of Vinyl Sulfones as Inhibitors of Complement-Dependent Cytotoxicity in Neuromyelitis Optica. Ju EJ; Yeon SK; Park JH; Cheon SY; Choi JW; Ha T; Jang BK; Kim S; Kang YG; Hwang H; Cho SJ; Cheong E; Bahn YS; Pae AN; Kim SM; Park KD ChemMedChem; 2016 Feb; 11(4):377-81. PubMed ID: 26804736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]